{"id":"https://openalex.org/W2807835948","doi":"https://doi.org/10.1016/s2352-3018(18)30092-4","title":"Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial","display_name":"Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial","publication_year":2018,"publication_date":"2018-06-18","ids":{"openalex":"https://openalex.org/W2807835948","doi":"https://doi.org/10.1016/s2352-3018(18)30092-4","mag":"2807835948","pmid":"https://pubmed.ncbi.nlm.nih.gov/29925489"},"language":"en","primary_location":{"id":"doi:10.1016/s2352-3018(18)30092-4","doi":"https://doi.org/10.1016/s2352-3018(18)30092-4","is_oa":false,"landing_page_url":"https://doi.org/10.1016/s2352-3018(18)30092-4","pdf_url":null,"source":{"id":"https://openalex.org/S2531945440","display_name":"The Lancet HIV","issn_l":"2352-3018","issn":["2352-3018","2405-4704"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-class-a","anvur-scientific","cwts-core","dongbi-a","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Lancet HIV","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5046238828","display_name":"Jean\u2010Michel Molina","orcid":"https://orcid.org/0000-0001-8684-2214","observed_orcids":["https://orcid.org/0000-0001-8684-2214","https://orcid.org/0000-0002-6711-8754"]},"institutions":[{"id":"https://openalex.org/I4210097159","display_name":"Assistance Publique \u2013 H\u00f4pitaux de Paris","ror":"https://ror.org/00pg5jh14","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I4210097159"]},{"id":"https://openalex.org/I4210144610","display_name":"H\u00f4pital Saint-Louis","ror":"https://ror.org/049am9t04","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I4210097159","https://openalex.org/I4210144610"]},{"id":"https://openalex.org/I4387154366","display_name":"Universit\u00e9 Paris Diderot","ror":"https://ror.org/02n7qrg46","country_code":"FR","type":"education","lineage":["https://openalex.org/I204730241","https://openalex.org/I4387154366"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Jean-Michel Molina","raw_affiliation_strings":["Department of Infectious Diseases, Saint-Louis Hospital, Paris, France; Assitance Publique H\u00f4pitaux de Paris, Paris, France; University of Paris Diderot, Paris France","Assitance Publique H\u00f4pitaux de Paris, Paris, France","Department of Infectious Diseases, Saint-Louis Hospital, Paris, France","University of Paris Diderot, Paris France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Infectious Diseases, Saint-Louis Hospital, Paris, France; Assitance Publique H\u00f4pitaux de Paris, Paris, France; University of Paris Diderot, Paris France","institution_ids":["https://openalex.org/I4210144610","https://openalex.org/I4387154366"]},{"raw_affiliation_string":"Assitance Publique H\u00f4pitaux de Paris, Paris, France","institution_ids":["https://openalex.org/I4210097159"]},{"raw_affiliation_string":"Department of Infectious Diseases, Saint-Louis Hospital, Paris, France","institution_ids":["https://openalex.org/I4210144610"]},{"raw_affiliation_string":"University of Paris Diderot, Paris France","institution_ids":["https://openalex.org/I4387154366"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103367960","display_name":"Douglas J. Ward","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Douglas Ward","raw_affiliation_strings":["Dupont Circle Physicians Group, Washington, DC, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dupont Circle Physicians Group, Washington, DC, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5011435304","display_name":"Indira Brar","orcid":"https://orcid.org/0000-0002-0568-6457","observed_orcids":["https://orcid.org/0000-0002-0568-6457"]},"institutions":[{"id":"https://openalex.org/I2803043754","display_name":"Henry Ford Hospital","ror":"https://ror.org/0193sb042","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I154057602","https://openalex.org/I2803043754"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Indira Brar","raw_affiliation_strings":["Henry Ford Hospital, Detroit, MI, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Henry Ford Hospital, Detroit, MI, USA","institution_ids":["https://openalex.org/I2803043754"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5073100933","display_name":"Anthony Mills","orcid":"https://orcid.org/0000-0002-6997-5581","observed_orcids":["https://orcid.org/0000-0002-6997-5581"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Anthony Mills","raw_affiliation_strings":["Southern California Men's Medical Group, Los Angeles, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Southern California Men's Medical Group, Los Angeles, CA, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111965428","display_name":"Hans\u2010J\u00fcrgen Stellbrink","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210116308","display_name":"Infektionsmedizinisches Centrum Hamburg","ror":"https://ror.org/01mp0e364","country_code":"DE","type":"facility","lineage":["https://openalex.org/I4210116308"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Hans-J\u00fcrgen Stellbrink","raw_affiliation_strings":["Infectious Disease Medical Center, Hamburg, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Infectious Disease Medical Center, Hamburg, Germany","institution_ids":["https://openalex.org/I4210116308"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5047687363","display_name":"Luis Fernando L\u00f3pez-Cort\u00e9s","orcid":"https://orcid.org/0000-0002-3804-3458","observed_orcids":["https://orcid.org/0000-0002-3804-3458"]},"institutions":[{"id":"https://openalex.org/I134820265","display_name":"Consejo Superior de Investigaciones Cient\u00edficas","ror":"https://ror.org/02gfc7t72","country_code":"ES","type":"government","lineage":["https://openalex.org/I134820265"]},{"id":"https://openalex.org/I4210133602","display_name":"Instituto de Biomedicina de Sevilla","ror":"https://ror.org/031zwx660","country_code":"ES","type":"facility","lineage":["https://openalex.org/I134820265","https://openalex.org/I158283456","https://openalex.org/I4210133602","https://openalex.org/I79238269","https://openalex.org/I918821925"]},{"id":"https://openalex.org/I4210153139","display_name":"Hospital Universitario Virgen del Roc\u00edo","ror":"https://ror.org/04vfhnm78","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I4210153139"]},{"id":"https://openalex.org/I79238269","display_name":"Universidad de Sevilla","ror":"https://ror.org/03yxnpp24","country_code":"ES","type":"education","lineage":["https://openalex.org/I79238269"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Luis L\u00f3pez-Cort\u00e9s","raw_affiliation_strings":["Unidad Cl\u00ednica de Enfermedades Infecciosas, Microbiolog\u00eda y Medicina Preventiva, Hospital Universitario Virgen del Roc\u00edo/Instituto de Biomedicina de Sevilla/Consejo Superior de Investigaciones Cient\u00edficas/Universidad de Sevilla, Seville, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Unidad Cl\u00ednica de Enfermedades Infecciosas, Microbiolog\u00eda y Medicina Preventiva, Hospital Universitario Virgen del Roc\u00edo/Instituto de Biomedicina de Sevilla/Consejo Superior de Investigaciones Cient\u00edficas/Universidad de Sevilla, Seville, Spain","institution_ids":["https://openalex.org/I134820265","https://openalex.org/I4210133602","https://openalex.org/I4210153139","https://openalex.org/I79238269"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5089993955","display_name":"Peter Jerome Ruane","orcid":"https://orcid.org/0000-0002-7170-9928","observed_orcids":["https://orcid.org/0000-0002-7170-9928"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Peter Ruane","raw_affiliation_strings":["Peter J Ruane, MD, Los Angeles, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Peter J Ruane, MD, Los Angeles, CA, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5107517502","display_name":"Daniel Podzamczer","orcid":"https://orcid.org/0000-0001-7090-3561","observed_orcids":["https://orcid.org/0000-0001-7090-3561"]},"institutions":[{"id":"https://openalex.org/I2802050225","display_name":"Bellvitge University Hospital","ror":"https://ror.org/00epner96","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I157913058","https://openalex.org/I2802050225","https://openalex.org/I4210153292"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Daniel Podzamczer","raw_affiliation_strings":["Hospital Universitari de Bellvitge, Barcelona, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hospital Universitari de Bellvitge, Barcelona, Spain","institution_ids":["https://openalex.org/I2802050225"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110434587","display_name":"Cynthia C Brinson","orcid":"https://orcid.org/0000-0002-3024-2815","observed_orcids":["https://orcid.org/0000-0002-3024-2815"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Cynthia Brinson","raw_affiliation_strings":["Central Texas Clinical Research, Austin, TX, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Central Texas Clinical Research, Austin, TX, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5104179065","display_name":"Joseph M. Custodio","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210140816","display_name":"Gilead Sciences (United States)","ror":"https://ror.org/056546b03","country_code":"US","type":"company","lineage":["https://openalex.org/I4210140816"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Joseph Custodio","raw_affiliation_strings":["Gilead Sciences, Foster City, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Gilead Sciences, Foster City, CA, USA","institution_ids":["https://openalex.org/I4210140816"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100387678","display_name":"Hui Liu","orcid":"https://orcid.org/0009-0002-1407-0117","observed_orcids":["https://orcid.org/0009-0002-1407-0117"]},"institutions":[{"id":"https://openalex.org/I4210140816","display_name":"Gilead Sciences (United States)","ror":"https://ror.org/056546b03","country_code":"US","type":"company","lineage":["https://openalex.org/I4210140816"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Hui Liu","raw_affiliation_strings":["Gilead Sciences, Foster City, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Gilead Sciences, Foster City, CA, USA","institution_ids":["https://openalex.org/I4210140816"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5080996117","display_name":"Kristen N. Andreatta","orcid":"https://orcid.org/0009-0004-7201-533X","observed_orcids":["https://orcid.org/0009-0004-7201-533X"]},"institutions":[{"id":"https://openalex.org/I4210140816","display_name":"Gilead Sciences (United States)","ror":"https://ror.org/056546b03","country_code":"US","type":"company","lineage":["https://openalex.org/I4210140816"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kristen Andreatta","raw_affiliation_strings":["Gilead Sciences, Foster City, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Gilead Sciences, Foster City, CA, USA","institution_ids":["https://openalex.org/I4210140816"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5026987150","display_name":"Hal Martin","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210140816","display_name":"Gilead Sciences (United States)","ror":"https://ror.org/056546b03","country_code":"US","type":"company","lineage":["https://openalex.org/I4210140816"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Hal Martin","raw_affiliation_strings":["Gilead Sciences, Foster City, CA, USA. Electronic address: hal.martin@gilead.com","Gilead Sciences, Foster City, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Gilead Sciences, Foster City, CA, USA. Electronic address: hal.martin@gilead.com","institution_ids":["https://openalex.org/I4210140816"]},{"raw_affiliation_string":"Gilead Sciences, Foster City, CA, USA","institution_ids":["https://openalex.org/I4210140816"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5001632717","display_name":"Andrew Cheng","orcid":"https://orcid.org/0000-0002-1121-8051","observed_orcids":["https://orcid.org/0000-0002-1121-8051"]},"institutions":[{"id":"https://openalex.org/I4210140816","display_name":"Gilead Sciences (United States)","ror":"https://ror.org/056546b03","country_code":"US","type":"company","lineage":["https://openalex.org/I4210140816"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Andrew Cheng","raw_affiliation_strings":["Gilead Sciences, Foster City, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Gilead Sciences, Foster City, CA, USA","institution_ids":["https://openalex.org/I4210140816"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5028586840","display_name":"Erin K. Quirk","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210140816","display_name":"Gilead Sciences (United States)","ror":"https://ror.org/056546b03","country_code":"US","type":"company","lineage":["https://openalex.org/I4210140816"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Erin Quirk","raw_affiliation_strings":["Gilead Sciences, Foster City, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Gilead Sciences, Foster City, CA, USA","institution_ids":["https://openalex.org/I4210140816"]}]}],"institutions":[],"countries_distinct_count":4,"institutions_distinct_count":11,"corresponding_author_ids":["https://openalex.org/A5026987150"],"corresponding_institution_ids":["https://openalex.org/I4210140816"],"apc_list":{"value":7280,"currency":"USD","value_usd":7280},"apc_paid":null,"fwci":12.5971,"has_fulltext":false,"cited_by_count":208,"citation_normalized_percentile":{"value":0.99335344,"is_in_top_1_percent":true,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":98,"max":100},"biblio":{"volume":"5","issue":"7","first_page":"e357","last_page":"e365"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10526","display_name":"HIV/AIDS drug development and treatment","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10526","display_name":"HIV/AIDS drug development and treatment","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10082","display_name":"HIV/AIDS Research and Interventions","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10112","display_name":"HIV Research and Treatment","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2406","display_name":"Virology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/bictegravir","display_name":"bictegravir","score":0.7200000286102295},{"id":"https://openalex.org/keywords/emtricitabine","display_name":"emtricitabine","score":0.9369999766349792},{"id":"https://openalex.org/keywords/tenofovir-alafenamide","display_name":"tenofovir alafenamide","score":1.0},{"id":"https://openalex.org/keywords/dolutegravir","display_name":"dolutegravir","score":0.9739999771118164},{"id":"https://openalex.org/keywords/abacavir","display_name":"abacavir","score":0.996999979019165},{"id":"https://openalex.org/keywords/lamivudine","display_name":"lamivudine","score":0.9959999918937683},{"id":"https://openalex.org/keywords/hiv-1-infection","display_name":"HIV-1 infection","score":0.8790000081062317},{"id":"https://openalex.org/keywords/antiretroviral-therapy-switching","display_name":"antiretroviral therapy switching","score":0.8159999847412109},{"id":"https://openalex.org/keywords/viral-suppression","display_name":"viral suppression","score":0.8130000233650208},{"id":"https://openalex.org/keywords/non-inferiority","display_name":"non-inferiority","score":0.8500000238418579},{"id":"https://openalex.org/keywords/viral-rebound","display_name":"viral rebound","score":0.48100000619888306},{"id":"https://openalex.org/keywords/treatment-emergent-resistance","display_name":"treatment-emergent resistance","score":0.6869999766349792},{"id":"https://openalex.org/keywords/drug-drug-interactions","display_name":"drug-drug interactions","score":0.5370000004768372},{"id":"https://openalex.org/keywords/renal-safety","display_name":"renal safety","score":0.4410000145435333},{"id":"https://openalex.org/keywords/lipid-profile","display_name":"lipid profile","score":0.33000001311302185}],"concepts":[{"id":"https://openalex.org/C2779502633","wikidata":"https://www.wikidata.org/wiki/Q937224","display_name":"Dolutegravir","level":5,"score":0.9318503141403198},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9202614426612854},{"id":"https://openalex.org/C2779465607","wikidata":"https://www.wikidata.org/wiki/Q304330","display_name":"Abacavir","level":5,"score":0.8429185152053833},{"id":"https://openalex.org/C2779778239","wikidata":"https://www.wikidata.org/wiki/Q422604","display_name":"Emtricitabine","level":5,"score":0.7518424987792969},{"id":"https://openalex.org/C2777869810","wikidata":"https://www.wikidata.org/wiki/Q422631","display_name":"Lamivudine","level":4,"score":0.7338886260986328},{"id":"https://openalex.org/C2911190787","wikidata":"https://www.wikidata.org/wiki/Q22075912","display_name":"Tenofovir alafenamide","level":5,"score":0.6524286866188049},{"id":"https://openalex.org/C2776623344","wikidata":"https://www.wikidata.org/wiki/Q5456317","display_name":"Fixed-dose combination","level":2,"score":0.43688809871673584},{"id":"https://openalex.org/C3013748606","wikidata":"https://www.wikidata.org/wiki/Q15787","display_name":"Human immunodeficiency virus (HIV)","level":2,"score":0.42934805154800415},{"id":"https://openalex.org/C2777844706","wikidata":"https://www.wikidata.org/wiki/Q422504","display_name":"Deoxycytidine","level":4,"score":0.4207378923892975},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.3653956651687622},{"id":"https://openalex.org/C29456083","wikidata":"https://www.wikidata.org/wiki/Q1221899","display_name":"Gynecology","level":1,"score":0.3336098790168762},{"id":"https://openalex.org/C159047783","wikidata":"https://www.wikidata.org/wiki/Q7215","display_name":"Virology","level":1,"score":0.30851447582244873},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.28694620728492737},{"id":"https://openalex.org/C2993143319","wikidata":"https://www.wikidata.org/wiki/Q583050","display_name":"Antiretroviral therapy","level":4,"score":0.19970309734344482},{"id":"https://openalex.org/C142462285","wikidata":"https://www.wikidata.org/wiki/Q2528140","display_name":"Viral load","level":3,"score":0.15593042969703674},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.12876445055007935},{"id":"https://openalex.org/C2522874641","wikidata":"https://www.wikidata.org/wiki/Q808","display_name":"Virus","level":2,"score":0.0697651207447052},{"id":"https://openalex.org/C2780258809","wikidata":"https://www.wikidata.org/wiki/Q414143","display_name":"Gemcitabine","level":3,"score":0.0},{"id":"https://openalex.org/C2780593183","wikidata":"https://www.wikidata.org/wiki/Q6844","display_name":"Hepatitis B virus","level":3,"score":0.0}],"mesh":[{"descriptor_ui":"D000068679","descriptor_name":"Emtricitabine","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000068679","descriptor_name":"Emtricitabine","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000068679","descriptor_name":"Emtricitabine","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D000068698","descriptor_name":"Tenofovir","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000068698","descriptor_name":"Tenofovir","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000068698","descriptor_name":"Tenofovir","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D000072230","descriptor_name":"Sustained Virologic Response","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000099226","descriptor_name":"Dolutegravir","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000099227","descriptor_name":"Abacavir","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000577","descriptor_name":"Amides","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004311","descriptor_name":"Double-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004359","descriptor_name":"Drug Therapy, Combination","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006575","descriptor_name":"Heterocyclic Compounds, 3-Ring","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D006575","descriptor_name":"Heterocyclic Compounds, 3-Ring","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D006575","descriptor_name":"Heterocyclic Compounds, 3-Ring","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D006576","descriptor_name":"Heterocyclic Compounds, 4 or More Rings","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D006576","descriptor_name":"Heterocyclic Compounds, 4 or More Rings","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D006576","descriptor_name":"Heterocyclic Compounds, 4 or More Rings","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D006679","descriptor_name":"HIV Seropositivity","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010078","descriptor_name":"Oxazines","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010879","descriptor_name":"Piperazines","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011728","descriptor_name":"Pyridones","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015224","descriptor_name":"Dideoxynucleosides","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D015224","descriptor_name":"Dideoxynucleosides","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D015224","descriptor_name":"Dideoxynucleosides","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D015497","descriptor_name":"HIV-1","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true},{"descriptor_ui":"D015658","descriptor_name":"HIV Infections","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D015658","descriptor_name":"HIV Infections","qualifier_ui":"Q000821","qualifier_name":"virology","is_major_topic":false},{"descriptor_ui":"D019259","descriptor_name":"Lamivudine","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D019259","descriptor_name":"Lamivudine","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D019259","descriptor_name":"Lamivudine","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D019380","descriptor_name":"Anti-HIV Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D019380","descriptor_name":"Anti-HIV Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D019380","descriptor_name":"Anti-HIV Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D019562","descriptor_name":"Viral Load","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D055815","descriptor_name":"Young Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D057915","descriptor_name":"Drug Substitution","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D064420","descriptor_name":"Drug-Related Side Effects and Adverse Reactions","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1016/s2352-3018(18)30092-4","doi":"https://doi.org/10.1016/s2352-3018(18)30092-4","is_oa":false,"landing_page_url":"https://doi.org/10.1016/s2352-3018(18)30092-4","pdf_url":null,"source":{"id":"https://openalex.org/S2531945440","display_name":"The Lancet HIV","issn_l":"2352-3018","issn":["2352-3018","2405-4704"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-class-a","anvur-scientific","cwts-core","dongbi-a","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Lancet HIV","raw_type":"journal-article"},{"id":"pmid:29925489","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/29925489","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The lancet. HIV","raw_type":"Clinical Trial, Phase III"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[{"id":"https://openalex.org/F4320308573","display_name":"Gilead Sciences","ror":"https://ror.org/056546b03"}],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":15,"referenced_works":["https://openalex.org/W2076175848","https://openalex.org/W2192719364","https://openalex.org/W2323452366","https://openalex.org/W2521726183","https://openalex.org/W2523305619","https://openalex.org/W2554692247","https://openalex.org/W2556153964","https://openalex.org/W2562322368","https://openalex.org/W2586083164","https://openalex.org/W2612496400","https://openalex.org/W2752494178","https://openalex.org/W2753489952","https://openalex.org/W2792700333","https://openalex.org/W2807931585","https://openalex.org/W4239743462"],"related_works":["https://openalex.org/W2807931585","https://openalex.org/W2807973130","https://openalex.org/W2944376193","https://openalex.org/W4244459571","https://openalex.org/W4407872582","https://openalex.org/W3033333369","https://openalex.org/W3042726352","https://openalex.org/W7160406362","https://openalex.org/W7128058979","https://openalex.org/W2803164097"],"abstract_inverted_index":null,"counts_by_year":[{"year":2026,"cited_by_count":18},{"year":2025,"cited_by_count":38},{"year":2024,"cited_by_count":32},{"year":2023,"cited_by_count":34},{"year":2022,"cited_by_count":20},{"year":2021,"cited_by_count":21},{"year":2020,"cited_by_count":20},{"year":2019,"cited_by_count":18},{"year":2018,"cited_by_count":7}],"updated_date":"2026-11-11T12:16:26.678958","created_date":"2018-06-21T00:00:00"}